Nothing Special   »   [go: up one dir, main page]

EP1178815A4 - Death domain containing receptors - Google Patents

Death domain containing receptors

Info

Publication number
EP1178815A4
EP1178815A4 EP00926218A EP00926218A EP1178815A4 EP 1178815 A4 EP1178815 A4 EP 1178815A4 EP 00926218 A EP00926218 A EP 00926218A EP 00926218 A EP00926218 A EP 00926218A EP 1178815 A4 EP1178815 A4 EP 1178815A4
Authority
EP
European Patent Office
Prior art keywords
domain containing
death domain
containing receptors
receptors
death
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00926218A
Other languages
German (de)
French (fr)
Other versions
EP1178815A1 (en
Inventor
Guo-Liang Yu
Jian Ni
Reiner L Gentz
Patrick J Dillon
Vishva M Dixit
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
University of Michigan
Original Assignee
Human Genome Sciences Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, University of Michigan filed Critical Human Genome Sciences Inc
Publication of EP1178815A1 publication Critical patent/EP1178815A1/en
Publication of EP1178815A4 publication Critical patent/EP1178815A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP00926218A 1999-04-22 2000-04-21 Death domain containing receptors Withdrawn EP1178815A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13048899P 1999-04-22 1999-04-22
US130488P 1999-04-22
US13674199P 1999-05-28 1999-05-28
US136741P 1999-05-28
PCT/US2000/010741 WO2000064465A1 (en) 1999-04-22 2000-04-21 Death domain containing receptors

Publications (2)

Publication Number Publication Date
EP1178815A1 EP1178815A1 (en) 2002-02-13
EP1178815A4 true EP1178815A4 (en) 2003-02-05

Family

ID=26828526

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00926218A Withdrawn EP1178815A4 (en) 1999-04-22 2000-04-21 Death domain containing receptors

Country Status (5)

Country Link
EP (1) EP1178815A4 (en)
JP (1) JP2003522118A (en)
AU (1) AU4478200A (en)
CA (1) CA2371114A1 (en)
WO (1) WO2000064465A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0904366A1 (en) 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
WO2001035995A2 (en) * 1999-11-19 2001-05-25 Tittle Thomas V Tr3-specific binding agents and methods for their use
US6994976B1 (en) 1999-11-19 2006-02-07 Tittle Thomas V Tr3-specific binding agents and methods for their use
WO2003013581A1 (en) * 2001-08-03 2003-02-20 Genset S.A. Agonists and antagonists of genceptin for the treatment of metabolic disorders
EP1361433A3 (en) * 2002-04-09 2005-02-23 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Method for estimating therapeutic efficacy of tumor necrosis factor (TNF)
WO2005018571A2 (en) * 2003-08-20 2005-03-03 University Of Miami Compositions and methods for treating inflammatory lung disease
JP2008525002A (en) * 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム BCMA polypeptides and uses thereof
BRPI0617057A2 (en) 2005-08-30 2011-07-12 Univ Miami isolated antibody, tumor necrosis factor 25 receptor-specific toxin (tnfr25), method for activating tumor necrosis factor 25 receptor (tnfr25), method for inhibiting tumor necrosis factor 25 receptor (tnfr25) signaling in a cell , antitumor vaccine, method for immunizing a patient against tumor, method for treating cancer in a patient, method for treating and / or preventing intestinal inflammation, therapeutic composition for facilitating an organ transplant, method for transplanting tissue from a donor to a host, method for inhibiting clonal expression of a cognate cd8 t cell population, method for treating and / or preventing pulmonary inflammation, isolated tnfr25 antagonist, composition and expression vector
CA2806840C (en) 2009-08-03 2019-08-27 Eckhard R. Podack Method for in vivo expansion of t regulatory cells
WO2012117067A1 (en) * 2011-03-01 2012-09-07 Novo Nordisk A/S Antagonistic dr3 ligands
KR20210041631A (en) 2013-01-09 2021-04-15 유니버시티 오브 마이애미 Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
SG11201608253XA (en) * 2014-04-04 2016-10-28 Kyowa Hakko Kirin Co Ltd Anti-death receptor 3 (dr3) antagonistic antibodies with reduced agonistic activity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5120525A (en) * 1988-03-29 1992-06-09 Immunomedics, Inc. Radiolabeled antibody cytotoxic therapy of cancer
US5656272A (en) * 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
EP0904366A1 (en) * 1996-04-01 1999-03-31 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
ES2284199T5 (en) * 1997-01-28 2011-11-14 Human Genome Sciences, Inc. RECEIVER 4 CONTAINING DEATH DOMAIN (DR4: DEATH RECEIVER 4), MEMBER OF THE TNF RECEPTORS SUPERFAMILY AND TRAIL UNION (APO-2L).

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033904A1 (en) * 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CHEN GANG ET AL: "Induction of p53-independent apoptosis by hygromycin B: Suppression by Bcl-2 and adenovirus E1B 19-kDa protein.", EXPERIMENTAL CELL RESEARCH, vol. 221, no. 1, 1995, pages 55 - 59, XP002208668, ISSN: 0014-4827 *
CHINNAIYAN A M ET AL: "SIGNAL TRANSDUCTION BY DR3, A DEATH DOMAIN-CONTAINING RECEPTOR RELATED TO TNFR-1 AND CD95", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 274, no. 5289, 8 November 1996 (1996-11-08), pages 990 - 992, XP000676685, ISSN: 0036-8075 *
COTTER T G ET AL: "THE INDUCTION OF APOPTOSIS BY CHEMOTHERAPEUTIC AGENTS OCCURS IN ALLPHASES OF THE CELL CYCLE", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 12, May 1992 (1992-05-01), pages 773 - 779, XP000944551, ISSN: 0250-7005 *
HUSS R ET AL: "Cyclosporine-induced apoptosis in CD4+ T lymphocytes and computer-simulated analysis: Modeling a treatment scenario for HIV infection.", RESEARCH IN IMMUNOLOGY, vol. 146, no. 2, 1995, pages 101 - 108, XP002208870, ISSN: 0923-2494 *
See also references of WO0064465A1 *
VAN ANTWERP DANIEL J ET AL: "Inhibition of TNF-induced apoptosis by NF-kB.", TRENDS IN CELL BIOLOGY, vol. 8, no. 3, March 1998 (1998-03-01), pages 107 - 111, XP002208872, ISSN: 0962-8924 *
WALTER DIRK H ET AL: "Cyclosporin A inhibits apoptosis of human endothelial cells by preventing release of cytochrome C from mitochondria.", CIRCULATION, vol. 98, no. 12, pages 1153 - 1157, XP002208865, ISSN: 0009-7322 *
WANG EDDIE C Y ET AL: "DR3 regulates negative selection during thymocyte development.", MOLECULAR AND CELLULAR BIOLOGY, vol. 21, no. 10, May 2001 (2001-05-01), pages 3451 - 3461, XP002208363, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
CA2371114A1 (en) 2000-11-02
JP2003522118A (en) 2003-07-22
AU4478200A (en) 2000-11-10
WO2000064465A1 (en) 2000-11-02
EP1178815A1 (en) 2002-02-13

Similar Documents

Publication Publication Date Title
PL350095A1 (en) Ligands of melanocortinic receptors
HUP0203375A3 (en) Substituted oxoazaheterocyclyl compounds
GB2357761B (en) Compounds
IL149283A0 (en) Decoy
EP1196191A4 (en) Death domain containing receptor 5
EP1178815A4 (en) Death domain containing receptors
EP1200472A4 (en) Odorant receptors
AU4984300A (en) Death domain containing receptor 4
GB2360990B (en) Soap wrappers
GB9902399D0 (en) Compounds
GB9911456D0 (en) Oligohydroxyl substituted 3-urea-benzofurane-and-pyridofurane-derivatives
GB2349365B (en) Easy cover
GB9905498D0 (en) Expression
EP1161453A4 (en) Cytokine-binding domain
AU1115197A (en) Death domain containing receptors
GB9904985D0 (en) Hydrocarbons
SI1077935T1 (en) Phenylsulfonamide-phenylethylamines useful as dopamine receptors
TW402863U (en) Protecting sleeve for simulated bait
GB9902419D0 (en) Protein domain
GB9917089D0 (en) Oil container
GB9905495D0 (en) Fungicide use
GB9906793D0 (en) Oil
GB9912128D0 (en) Oil
GB9927609D0 (en) Enhanced expression
GB9910482D0 (en) Decoy

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011122

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/00 A, 7A 61K 39/00 B, 7C 07K 14/435 B, 7C 07K 14/47 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021220

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060919